top of page
31975-site-vettiva-hero2.jpg

R&D

31975-site-vettiva-imagem7.jpg

The development of new drugs is a long, rigorous, and expensive process. Our efforts and activities to develop innovative therapeutic candidates based on cannabidiol began in 2018. As a company with solid experience in developing exceptional drugs for human health, we have integrated into our pipeline all stages of pharmaceutical and clinical development required by animal health regulatory agencies (Preclinical Studies and Clinical Research), as well as state-of-the-art technologies adopted in human health to scientifically prove the benefits of cannabidiol for various pathologies in dogs and cats.

cachorro e gato filhotes no veterinário recebendo cuidado

Our first innovative drug is expected to launch in mid-2023, and our R&D pipeline includes several therapeutic candidates in development for the treatment of several highly prevalent conditions in which there is a high demand for more effective and/or safer therapies in dogs and cats. The pharmaceutical development and full manufacturing of Vettiva’s therapeutic candidates are carried out at a pharmaceutical plant certified by the FDA and other global regulatory agencies in the United States.

31975-site-vettiva-imagem5.png

Product Pipeline

Research and development stages for the new drug:

ACCESS

Discovery of the substance

  • Biological and pathophysiological evaluation of the disease;

  • Identifies and validates targets;

  • Molecule tracking;

  • Laboratory tests.

PRE-CLINICAL PHASE

In vitro and in vivo tests

  • Safety and toxicity studies;

  • Initial formulation;

  • Assessment of pharmacokinetics and pharmacodynamics.

CLINICAL PHASE I

Safety dose assessment

  • Discovery of markers for safety and toxicity;

  • Determines the optimal dose to be tested;

  • Pharmacokinetic assessment.

CLINICAL PHASE II

Assessment of potential efficacy and safety

  • Measures preliminary effectiveness;

  • Investigates the occurrence of adverse effects;

  • Determines dose and dosage;

  • Inclusion and exclusion criteria.

CLINICAL PHASE III

Evaluation of efficacy and safety

  • Assessment of efficacy, safety, interactions, and contraindications in the medium term;

  • Multicenter, comparative studies;

  • Restricted inclusion and exclusion criteria.

gato olhando para cima

APPROVAL BY MAP

Post-market evaluation

  • Assesses effectiveness, risks, safety and long-term benefits;

  • Allows assessment of rare side effects.

*Legal Disclaimer: Vettiva does not sell any products. All current activities of the company are exclusively within the scope of research and development of medicines. All information contained on this website is not for commercial and/or product promotional purposes.

bottom of page